How state-mandated formularies impact costs November 12, 2016By Tracey WalkerResearch by Express Scripts presented at the AMCP examines costs among Medicaid members in the Florida plan to members in a similar Medicaid plan without a state-mandated formulary. Four things health execs should know about the oncology pipelineHere’s how you can recognize changes in the oncology pipeline and maximize value related to cancer care. Insurer: No more prior auths for opioid addiction meds October 27, 2016By Tracey WalkerAs part of efforts to combat the opioid epidemic, Cigna removes prior authorization from medication-assisted treatment for opioid use disorder. Online drug pricing tools that influence consumers October 25, 2016By Mari EdlinConsumers are demanding transparency in the prices of drugs. Here’s how they are getting it. Copay assistance programs: Managed care pros and consDo copay assistance program offer a long-term solution for patients? Experts weigh in. Are oncology pathways effective? AMCP presenters weigh in October 06, 2016By Aubrey WestgateFaced with a proliferation of oncology treatments, payers have started using oncology pathways. But what do these programs look like, and are they really working? Study: Use of short-acting opioids decrease, long-acting opioids increase October 06, 2016By Tracey WalkerExecutives need to increase awareness in the category and ensure prescribers are aware of CDC guidelines for opioid prescribing and the prescription drug monitoring programs. Nearly half of BCBS members discontinue this RA drug after 1 year October 05, 2016By Tracey WalkerAnalysis from Prime shows that improvements in persistency, adherence is key in RA treatments. Biosimilars and interchangeable biologics: News to watch October 05, 2016By Aubrey WestgateBiosimilars in the United States are slowly gaining traction, but widespread confusion and legal barriers remain. Drug pipeline developments: Alopecia areata and atopic dermatitisPromising treatments are coming for alopecia areata and atopic dermatitis, but they will come at a high cost.